The 36-month beta value for SPRY is also noteworthy at 0.91. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SPRY is 47.42M, and at present, short sellers hold a 14.51% of that float. The average trading volume of SPRY on July 19, 2024 was 571.99K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SPRY) stock’s latest price update
ARS Pharmaceuticals Inc (NASDAQ: SPRY) has seen a decline in its stock price by -7.81 in relation to its previous close of 11.33. However, the company has experienced a -5.99% decline in its stock price over the last five trading sessions. accesswire.com reported 2024-07-18 that LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SPRY’s Market Performance
ARS Pharmaceuticals Inc (SPRY) has seen a -5.99% fall in stock performance for the week, with a 24.20% gain in the past month and a 15.29% surge in the past quarter. The volatility ratio for the week is 7.08%, and the volatility levels for the past 30 days are at 6.61% for SPRY. The simple moving average for the past 20 days is 11.96% for SPRY’s stock, with a 47.56% simple moving average for the past 200 days.
Analysts’ Opinion of SPRY
Many brokerage firms have already submitted their reports for SPRY stocks, with Leerink Partners repeating the rating for SPRY by listing it as a “Outperform.” The predicted price for SPRY in the upcoming period, according to Leerink Partners is $18 based on the research report published on March 05, 2024 of the current year 2024.
SPRY Trading at 14.74% from the 50-Day Moving Average
After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.23% of loss for the given period.
Volatility was left at 6.61%, however, over the last 30 days, the volatility rate increased by 7.08%, as shares surge +29.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.53% upper at present.
During the last 5 trading sessions, SPRY fell by -5.99%, which changed the moving average for the period of 200-days by +176.32% in comparison to the 20-day moving average, which settled at $9.45. In addition, ARS Pharmaceuticals Inc saw 90.60% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRY starting from Tanimoto Sarina, who sale 100,000 shares at the price of $11.40 back on Jul 16 ’24. After this action, Tanimoto Sarina now owns 1,547,447 shares of ARS Pharmaceuticals Inc, valued at $1,140,295 using the latest closing price.
Lowenthal Richard E, the PRESIDENT AND CEO of ARS Pharmaceuticals Inc, sale 100,000 shares at $11.40 during a trade that took place back on Jul 16 ’24, which means that Lowenthal Richard E is holding 1,547,447 shares at $1,140,295 based on the most recent closing price.
Stock Fundamentals for SPRY
Current profitability levels for the company are sitting at:
- 3099.95 for the present operating margin
- 368.6 for the gross margin
The net margin for ARS Pharmaceuticals Inc stands at 2483.85. The total capital return value is set at -0.28. Equity return is now at value -20.49, with -19.93 for asset returns.
Based on ARS Pharmaceuticals Inc (SPRY), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -246.76. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -16.52.
Currently, EBITDA for the company is -67.45 million with net debt to EBITDA at 0.9. When we switch over and look at the enterprise to sales, we see a ratio of -47814.12. The receivables turnover for the company is -0.03for trailing twelve months and the total asset turnover is -0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 60.84.
Conclusion
In summary, ARS Pharmaceuticals Inc (SPRY) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
